Results 31 to 40 of about 5,253,073 (166)

'Being there' for women with metastatic breast cancer: a pan-European patient survey [PDF]

, 2013
Background: Understanding their experiences of diagnosis is integral to improving the quality of care for women living with advanced/metastatic breast cancer. Methods: A survey, initiated in March 2011, was conducted in two stages. First, the views of 47
V Harding, Krell, J, C J Twelves, Stebbing, J, Afshar, M, J Krell, Twelves, CJ, Ramaswami, R, J Stebbing, Harding, V, M Afshar, R Ramaswami   +11 more
core   +1 more source

Quality-of-Life Assessment in Pediatric Advanced Cancer: Development of the Patient-Reported Outcome Measure Advance QoL

Current Oncology
A recent measure was developed to assess the Quality of Life (QoL) of young people with advanced cancer and is available for parents and professionals (Advance QoL). The present study aimed to elaborate self-reported versions for children and adolescents
Lye-Ann Robichaud, Julie Felipe, Michel Duval, Bruno Michon, Marianne Olivier-D’Avignon, Sébastien Perreault, Mathias Tyo-Gomez, Marc-Antoine Marquis, Serge Sultan   +8 more
doaj   +1 more source

Advances in prostate cancer

Australian Journal of General Practice, 2020
Prostate cancer is a common tumour type in Australian men.The aim of this article is to review important changes in prostate cancer diagnosis and management over the past five years, particularly as they pertain to general practice.The management of prostate cancer has changed significantly in recent years, particularly the use of imaging, with the ...
Fairleigh A, Reeves, Niall M, Corcoran
openaire   +3 more sources

A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO).

, 2019
PURPOSE: To assess talazoparib activity in germline BRCA1/2 mutation carriers with advanced breast cancer. PATIENTS AND METHODS: ABRAZO (NCT02034916) was a two-cohort, two-stage, phase II study of talazoparib (1 mg/day) in germline BRCA mutation carriers
Grischke, E-M, Rugo, HS, Mailliez, A, Fasching, PA, Hannah, AL, Robson, ME, Chappey, C, Mina, LA, Hurvitz, SA, Turner, NC, Wardley, AM, Telli, ML, ABRAZO Study Group,, Ettl, J, Balmaña, J   +14 more
core   +1 more source

Effects of exercise intervention on sleep and survival in advanced cancer survivors: a meta-analysis of randomized controlled trials [PDF]

World Cancer Research Journal
Objective: The effectiveness of exercise in addressing sleep disturbance and improving survival outcomes among advanced cancer survivors remains inconsistent.
S. Liao, Y. Liu, W. Tang, Z. Zhang, M. Ha   +4 more
doaj   +1 more source

Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO Study. [PDF]

, 2021
PURPOSE: To investigate the activity of niraparib in patients with germline-mutated BRCA1/2 (gBRCAm) advanced breast cancer. PATIENTS AND METHODS: BRAVO was a randomized, open-label phase III trial. Eligible patients had gBRCAm and HER2-negative advanced
Trédan, O, Colleoni, M, Tutt, AN, Poncet, C, Láng, I, Goldstein, LJ, Erban, J, Goulioti, T, Cameron, DA, Audeh, W, Litière, S, Tryfonidis, K, Juan-Fita, MJ, Kaufman, B, Jen, KY, Musolino, A, Johannsson, OT, Mailliez, A, Honkoop, AH, Ignatiadis, M, Manso, L, Adam, V, Turner, NC, Razis, E, Ellard, SL, Zoppoli, G, Macpherson, IRJ, Vuylsteke, P, Balmaña, J, BRAVO Steering Committee and the BRAVO investigators,   +29 more
core   +1 more source

RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer.

, 2019
PURPOSE: Metastatic castration-resistant prostate cancer (mCRPC) is a lethal but clinically heterogeneous disease, with patients having variable benefit from endocrine and cytotoxic treatments.
Crespo, M, Makay, A, Rescigno, P, Mateo, J, Sharp, A, Romanel, A, McNair, C, Riisnaes, R, Carreira, S, Nava Rodrigues, D, Knudsen, K, Demichelis, F, de Bono, JS, Casiraghi, N, Miranda, S, Figueiredo, I, Sumanasuriya, S, Schiewer, M, Boysen, G, Gasperini, P   +19 more
core   +1 more source

Patients' and oncologists' views on the treatment and care of advanced ovarian cancer in the UK:results from the ADVOCATE study [PDF]

, 2013
Background:Most patients presenting with advanced ovarian cancer (AOC) eventually relapse. Symptom palliation, maintenance of quality of life (QoL) and prolongation of life are primary therapeutic goals.Methods:Sixty-six UK oncologists completed an ...
Monson, K, Susan Catt (4461673), S Banerjee (9892436), V Jenkins, I Solis-Trapala (7775843), I Solis-Trapala, C Gourley, A Montes (16163120), Jenkins, V, L Fallowfield, Montes, A, S Catt, K Monson, K Monson (13453767), Lesley Fallowfield (4461436), C Gourley (16163117), Valerie Jenkins (4460407), Gourley, C, S Banerjee, A Montes, Catt, S, Fallowfield, L, Banerjee, S, Solis-Trapala, I   +23 more
core   +1 more source

Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer: association with treatment effectiveness

Frontiers in Oncology
IntroductionCheckpoint inhibitors (CPI) are widely used in cancer treatment with a potential of causing immune-related adverse events (IRAEs). Several studies have reported a positive correlation between development of IRAEs and improved survival outcome.
Cecilia Olsson Ladjevardi, Cecilia Olsson Ladjevardi, Anthoula Koliadi, Anthoula Koliadi, Viktoria Rydén, Viktoria Rydén, Ali Inan El-Naggar, Evangelos Digkas, Evangelos Digkas, Antonios Valachis, Gustav J. Ullenhag, Gustav J. Ullenhag   +11 more
doaj   +1 more source

Childhood, adolescent and young adult cancer: cancer trends report

, 2023
This is the third Cancer Trends Report the National Cancer Registry Ireland (NCRI) has published on childhood cancers and the first to include cancers in adolescents and young adults (AYA) (up to 24 years of age).
National Cancer Registry Ireland (NCRI)
core